C3.ai vs. UiPath: Which Artificial Intelligence Stock Is a Better Investment in 2026?

UiPath is framed as the more compelling 2026 AI automation bet versus unprofitable C3.ai. C3.ai reported FY2026 revenue of $250.3M (-35.7% YoY) with a $470.4M net loss (net margin -187.9%) and FY2027 revenue guidance of $210M–$240M, while UiPath grew FY2026 revenue to $1.6B (+13% YoY) with net income of $282.3M (net margin 17.5%) and forecast FY2027 revenue of ~$1.8B. The article also highlights valuation support for UiPath (P/S 5.5x vs 5.9x for C3.ai; C3.ai lacks a forward P/E) despite risks like customer concentration and exposure to third-party cloud outages.

Analysis

This is less a thematic AI call than a quality/credibility dispersion trade. PATH is the cleaner beneficiary of IT spend migrating toward workflow automation with visible ROI; in a slower budget environment, buyers usually fund tools that remove labor hours, not speculative app layers. The second-order winner is Microsoft as the ultimate suite-bundler: if enterprises standardize around broad platforms, niche vendors with weaker distribution will face pricing pressure, but PATH’s installed base gives it a better shot at being the orchestration layer rather than a point solution.

AI looks more exposed to a prolonged reset in enterprise appetite for unproven consumption models. The key risk is that revenue softness is not just macro, but a sign that the product set is still too dependent on a few large relationships and too vulnerable to delayed purchasing decisions; that usually keeps multiples pinned even if liquidity is ample. If management can show a sustained reacceleration in the next 1-2 quarters, the short case weakens quickly; absent that, the market will likely continue to discount the stock as a show-me story.

Contrarian view: the consensus may be underestimating how much of PATH’s apparent improvement is already in the price, especially if SBC-adjusted economics disappoint or large-account expansion stalls. Conversely, AI may be over-discounted because its small revenue base can inflect faster than expected if a handful of government/industrial wins convert. The cleanest thesis horizon is 3-6 months for earnings/guidance confirmation, with 6-18 months favoring PATH if enterprise AI spend remains disciplined and vendor consolidation accelerates.

Key Decisions for Investors

• Initiate a beta-adjusted long PATH / short AI pair trade into the next earnings cycle; the spread should work if PATH sustains growth while AI remains a guide-down story.
• Use PATH as the preferred outright long in enterprise automation for a 6-12 month horizon, but size modestly and require continued revenue acceleration as the falsifier.
• Avoid adding to AI until management proves that consumption pricing is improving retention and not just delaying recognition; watch for a renewed revenue inflection before covering shorts.
• If you want convexity, consider PATH call spreads rather than outright shares to capture multiple expansion while capping disappointment from SBC scrutiny.
• Set a watch item on MSFT and other suite vendors: if they start bundling automation more aggressively, that is a medium-term headwind for PATH and a reason to reduce the pair.